3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇
3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇
3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 性质
| 熔点 | 144-147℃ |
|---|---|
| 沸点 | 630.6±65.0 °C(Predicted) |
| 密度 | 1.356 |
| 储存条件 | 2-8°C(protect from light) |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 14.93±0.10(Predicted) |
| 颜色 | 浅黄至黄色 |
3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 用途与合成方法
|
CDK1-Cyclin B 26 nM (IC 50 ) |
CDK2/cyclinE 3 nM (IC 50 ) |
cdk2/cyclin A 4 nM (IC 50 ) |
CDK4/cyclin D 216 nM (IC 50 ) |
Cdk5/p25 10 nM (IC 50 ) |
CDK7/cyclin H 200 nM (IC 50 ) |
CDK9/cycT 13 nM (IC 50 ) |
PKC
|
CGP60474 (Compound A) is a potent VEGFR-2 inhibitor, with an IC 50 of 84 nM. CGP60474 is also a PKC inhibitor, with competitive kinetics relative to ATP.
CGP-60474 (10 mg/kg; i.p.) inhibits the IL-6 level and increases the survival rate in the LPS endotoxemia model.
| Animal Model: | C57Bl/6 mice (LPS endotoxemia model) |
| Dosage: | 10 mg/kg |
| Administration: | I.p. |
| Result: | Had a higher survival rate. |
3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-11009 | 3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 | 164658-13-3 | 1 mg | 360 |
| 2026-06-05 | HY-11009 | 3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 | 164658-13-3 | 5mg | 850 |